Results 11 to 20 of about 64,429 (258)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity

open access: yesFrontiers in Cardiovascular Medicine, 2022
The cardiotoxicity of fluoropyrimidines (FP) [5-Fluorouracil and Capecitabine] is often reported as acute cardiac ischemia with rest typical angina, signs of ischemia at electrocardiogram (ECG), and ventricular kinetics abnormalities.
Linda Cucciniello   +5 more
doaj   +2 more sources

ICIs-related cardiotoxicity in different types of cancer [PDF]

open access: yes, 2022
Immune checkpoint inhibitors (ICIs) are rapidly developing immunotherapy cancer drugs that have prolonged patient survival. However, ICIs-related cardiotoxicity has been recognized as a rare, but fatal, consequence.
Zhang, Jing   +7 more
core   +1 more source

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review [PDF]

open access: yes, 2023
Introduction In the last few decades, there has been a rapid development in cancer therapies and improved detection strategies, hence the death rates caused by cancer have decreased.
Sam Salek   +4 more
core   +1 more source

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials [PDF]

open access: yes, 2010
Background: We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.Methods: Randomized controlled ...
Gill Levitt   +29 more
core   +2 more sources

Attenuation of Doxorubicin-Induced Cardiotoxicity by mdivi-1: A Mitochondrial Division/Mitophagy Inhibitor. [PDF]

open access: yes, 2013
Doxorubicin is one of the most effective anti-cancer agents. However, its use is associated with adverse cardiac effects, including cardiomyopathy and progressive heart failure.
Maddock Helen   +15 more
core   +2 more sources

Plasma N-Terminal Pro-Brain Natriuretic Peptide as Prognostic Marker in Fatal Cardial Decompensation with Sunitinib Malate Therapy [PDF]

open access: yes, 2010
A 74-year-old man with metastatic renal cell carcinoma and a history of cardiac failure was treated with sunitinib malate. MUGA echocardiography could not detect a relevant change in the ejection fraction although the clinical situation of the patient ...
Stief, Christian G.   +4 more
core   +1 more source

Cyclophosphamide-induced Cardiotoxicity with a Prolonged Clinical Course Diagnosed on an Endomyocardial Biopsy [PDF]

open access: yes, 2013
A 31-year-old woman with primary mediastinal large B-cell lymphoma refractory to conventional chemotherapy was treated with high-dose chemotherapy containing cyclophosphamide (CY).
Kusumoto, Saburo   +10 more
core   +1 more source

Nrf2: a dark horse in doxorubicin-induced cardiotoxicity

open access: yesCell Death Discovery, 2023
Being a broad-spectrum anticancer drug, doxorubicin is indispensable for clinical treatment. Unexpectedly, its cardiotoxic side effects have proven to be a formidable obstacle.
Xiaopeng Zhao   +3 more
doaj   +1 more source

Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies

open access: yesDiagnostics, 2023
Improvements in the treatment of childhood cancer have considerably enhanced survival rates over the last decades to over 80% as of today. However, this great achievement has been accompanied by the occurrence of several early and long-term treatment ...
Kondylia Antoniadi   +6 more
doaj   +1 more source

Doxorubicin Selectively Inhibits Brain versus Atrial Natriuretic Peptide Gene Expression in Cultured Neonatal Rat Myocytes [PDF]

open access: yes, 1999
Doxorubicin is an antineoplastic agent with significant cardiotoxicity. We examined the effects of this agent on the expression of the natriuretic peptide (NP) genes in cultured neonatal rat atrial myocytes.
Gardner, D. G.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy